Azora Therapeutics, Inc. (AZR)

Market Cap	49.99M
Revenue (ttm)	n/a
Net Income	n/a
EPS	n/a
Shares Out	14.24M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,064
Open	3.750
Previous Close	3.760
Day's Range	3.350 - 3.900
52-Week Range	1.310 - 7.200
Beta	n/a
Analysts	Strong Buy
Price Target	13.00 (+270.37%)
Est. Earnings	Nov 18, 2026

About AZR

Azora Therapeutics, Inc. operates as a biopharmaceutical company that develops small molecule new chemical entities for the treatment of autoimmune and inflammatory diseases. It offers treatment for dermatology and gastroenterology. The company's pipeline includes AT177, a colon‑targeted aryl hydrocarbon receptor (AhR) agonist to enable localized activation with limited systemic exposure in development for ulcerative colitis. Azora Therapeutics, Inc. was formerly known as Meya Pharmaceuticals, Inc. and changed its name to Azora Therapeutics, In...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 30, 2018
• Country: United States
• Stock Exchange: Nasdaq
• Ticker Symbol: AZR
• Website: https://www.azoratherapeutics.com

Analyst Summary

According to 3 analysts, the average rating for AZR stock is "Strong Buy." The 12-month stock price target is $13.0, which is an increase of 270.37% from the latest price.

Price Target

$13.0

(270.37% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Nov 12, 2026

Data Sources Report a data error